Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2003
03/06/2003WO2003018568A2 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
03/06/2003WO2003018566A1 New piperidinyl derivates as modulators of chemokine receptor activity
03/06/2003WO2003018564A1 Vascular wall-selective acat inhibitor
03/06/2003WO2003018561A1 N-type calcium channel antagonists for the treatment of pain
03/06/2003WO2003018557A1 Hydrazinopeptoids and their uses for treating cancers
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018545A1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3?
03/06/2003WO2003018542A1 Novel norstatin derivative
03/06/2003WO2003018538A1 Novel diarylalkene derivatives and novel diarylalkane derivatives
03/06/2003WO2003018515A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003WO2003018134A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003WO2003018060A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
03/06/2003WO2003018059A2 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
03/06/2003WO2003018058A1 Myocardial cell apoptosis inhibitors
03/06/2003WO2003018056A1 Stabilized preparations containing antibody
03/06/2003WO2003018045A1 A pharmaceutical being used for treating hiv infection, the composition and uses thereof
03/06/2003WO2003018032A1 Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
03/06/2003WO2003018025A1 Method and composition for treatment of ocular hypertension and glaucoma
03/06/2003WO2003018024A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
03/06/2003WO2003018022A1 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
03/06/2003WO2003018021A1 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003018010A1 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
03/06/2003WO2003018009A1 A combination of quetiapine and zolmitriptan
03/06/2003WO2003018008A1 Apo ai expression accelerating agent
03/06/2003WO2003018007A1 Antitumor agents and process for producing the same
03/06/2003WO2003018001A1 Apolipo protein e secretion promoters
03/06/2003WO2003018000A1 Novel ascorbic acid compounds, methods of synthesis and application
03/06/2003WO2003017998A1 Platinum complexes and their use in cancer treatment
03/06/2003WO2003017995A1 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity
03/06/2003WO2003017994A1 Amidine derivatives for treating amyloidosis
03/06/2003WO2003017993A1 Photoreactive compounds and compositions
03/06/2003WO2003017992A2 Means for treatment of atherosclerosis
03/06/2003WO2003017989A1 Compositions and techniques for localized therapy of restenosis
03/06/2003WO2003017983A1 A new extended release oral dosage form
03/06/2003WO2003017979A1 Method for the production of inhalation powders
03/06/2003WO2003017946A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003WO2003017940A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
03/06/2003WO2003017927A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003WO2003017921A2 A method to improve complexation efficacy and produce high-energy cyclodextrin-complexes
03/06/2003WO2003017769A1 Antimicrobial agent
03/06/2003WO2002102382A9 A PROCESS FOR PREPARING PAROXETINE HCl WHICH LIMITS FORMATION OF PINK COLORED COMPOUNDS
03/06/2003WO2002102381A9 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
03/06/2003WO2002100844A3 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
03/06/2003WO2002095026A8 Method of proliferating terminal differentiated cells and recombinant vector therefor
03/06/2003WO2002094830A3 DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002074243A9 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
03/06/2003WO2002072570A3 Non-imidazole compounds as histamine h3 antagonists
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002064092A3 Method for evaluating therapeutic efficacy
03/06/2003WO2002063961B1 Composition and methods for modulation of vascular structure and/or function
03/06/2003WO2002060972A3 Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002058692A9 Halogenated composition, method for preparing same and uses thereof
03/06/2003WO2002055507A8 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
03/06/2003WO2002055106A3 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
03/06/2003WO2002051994A8 Polypeptides
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002028481A3 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
03/06/2003WO2002026947A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/06/2003WO2002024672A3 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
03/06/2003WO2002022678A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/06/2003WO2002020516A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
03/06/2003WO2002012325A3 Suppressor gene
03/06/2003WO2002005797A8 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia
03/06/2003WO2002000650A9 Novel compounds possessing antibacterial, antifungal or antitumor activity
03/06/2003WO2001098343A9 Conserved diaphanous-related formin autoregulatory domain (dad)
03/06/2003WO2001077146A3 Compounds and methods for modulating endothelial cell adhesion
03/06/2003WO2001074900A9 Nuclear factor kb inducing factor
03/06/2003US20030045865 Compositions and techniques for localized therapy
03/06/2003US20030045830 Inhibiting the expression of a specific gene involved in eye function by inducing or reverting a mutation in that gene by topically applying or injecting the chimeric oligonucleotide
03/06/2003US20030045755 Polyamine analogues as cytotoxic agents
03/06/2003US20030045728 Indol-3-yl derivatives
03/06/2003US20030045721 Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
03/06/2003US20030045718 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
03/06/2003US20030045706 Method for preparing functionalised beta-(1,3)-glucan derivatives
03/06/2003US20030045602 Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
03/06/2003US20030045586 Use of amines
03/06/2003US20030045583 Novel succinate salt of O-desmethyl-venlafaxine
03/06/2003US20030045580 Making, by coating ibuprofen or its salt with hydroxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose or gelatin as binder, in specified weight percents; dosage forms
03/06/2003US20030045569 Difluoromethylene aromatic ethers as inhibitors of glycine transport
03/06/2003US20030045567 (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045563 Comprises cyclooxygenase-2 inhibitors (celecoxib, rofecoxib); water solubility; vasodilation/headache relief; for inhibition of precipitation and/or crystallization in gastrointestinal fluids
03/06/2003US20030045558 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides)
03/06/2003US20030045556 Aryl-N-cyanoguanidines and methods related thereto
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045553 Peroxisome proliferator-activated receptor agonists (PPAR) for increasing insulin sensitivity in treatment of diabetes and Syndrome X
03/06/2003US20030045552 Isoindole-imide compounds, compositions, and uses thereof
03/06/2003US20030045546 Anticancer agents
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045537 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same
03/06/2003US20030045535 Antiproliferative and antitumor agents
03/06/2003US20030045533 Phosphodiesterase 4 inhibitors
03/06/2003US20030045530 Administering a piperazine or piperidine coupled through a linker to a benzhydril
03/06/2003US20030045529 Method for specifically potentiating N-type Ca2+ channel activity
03/06/2003US20030045527 Treating central nervous system or gastrointestinal disorders
03/06/2003US20030045524 Particularly quinoxaline, (2-imidozolin-2-ylamino) quinoxaline, or 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline and linolenic acid, which may be complexed with the quinoxaline agonist
03/06/2003US20030045523 Nicotinic cholinergic receptor antagonists
1 ... 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 ... 1564